Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) EPS (Weighted Average and Diluted) (2020 - 2026)

GeneDx Holdings has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$2.16 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 839.13% to -$2.16 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.68 through Mar 2026, down 90.07% year-over-year, with the annual reading at -$0.73 for FY2025, 62.37% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$2.16 for Q1 2026 at GeneDx Holdings, down from -$0.61 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.36 in Q2 2025 and troughed at -$28.97 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$1.1 (2024), against an average of -$3.93.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 4300.0% in 2022 and then skyrocketed 132.73% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$28.97 in 2022, then soared by 96.82% to -$0.92 in 2023, then skyrocketed by 125.0% to $0.23 in 2024, then tumbled by 365.22% to -$0.61 in 2025, then tumbled by 254.1% to -$2.16 in 2026.
  • Per Business Quant, the three most recent readings for WGS's EPS (Weighted Average and Diluted) are -$2.16 (Q1 2026), -$0.61 (Q4 2025), and -$0.27 (Q3 2025).